Inspirna, Inc.

Aldeyra Therapeutics, Inc.

Nimbus Lakshmi, Inc.

Actimed Therapeutics Limited

Akamara Therapeutics, Inc.

Phoenix Molecular Designs

Third Harmonic Bio, Inc.

Takeda Pharmaceutical Company Limited

Jonathan James Loughrey

Eduardo J Martinez

Samuel Stratford

Stephen Wald

Amanda Buist

Joseph Benson

Stephen Gitu Machatha

Gregor Sneddon

Hannah Ruth McLachlan

Craig E Masse

Jeremy Robert Greenwood

Jon P Lawson

David Pearson

Jean-Baptiste Arlin

Jaclyn Raeburn

Gregg F Keaney

Ronnie Maxwell Lawrence

Attilia Figini

Sandra Dunn

Hayley Reece

Elaine McPherson

Saurabh Chitre

Charles Montgomery

Sarkar Arindam

Erik Flahive

Steven Krausert

Richard Winnike

Robin Chandra Bhattacherjee

Elaine Morten

Andrew Justin Stewart Coats

Kiara Marissa Lobato

Yuxiang Song

Leonard Walter Rozamus, Jr

Ivan Ruggiero

Gavin Pringle

Described herein are crystalline forms of (R)-N-(1-(4-aminobenzyl)-1H-pyrazol-4 -yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido [3′,2′: 4,5]-pyrrolo [1,2-a]pyrazine-2-carboxamide hydrochloride and solvates thereof; pharmaceutical compositions and use thereof in treating cancer such as breast cancer, prostate cancer, lung cancer, brain cancer, skin cancer, bone cancer, ovarian cancer, multiple myeloma and leukemia. Compound (I).

Crystalline forms of an RSK inhibitor

The present invention relates to metal salts of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid which exhibit improved physical properties and stability. The invention also relates to pharmaceutical compositions including an effective amount of the metal salts, as well as methods of treating cancer including administration of a pharmaceutical composition including a salt of the invention to a subject in need thereof.

Metal salts and uses thereof

The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S-pindolol; and (ii) an organic acid, wherein the organic acid has: a pKal of greater than or equal to 2.5; and a chemical formula of CHy(CO2H), where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2. The pharmaceutically acceptable acid addition salt is useful in treating conditions such as cachexia, sarcopenia, a neuromuscular disorder and muscle weakness.

Organic acid addition salts of S-pindolol

The present invention relates to free-base and salt forms, and compositions thereof of small molecule therapeutics acting as a scavenger for toxic aldehydes. The present invention further relates to use of the free-base and salt forms, and compositions thereof for treating diseases, disorders, or conditions in which aldehyde toxicity is implicated in their pathogenesis.

Polymorphic compounds and uses thereof

The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions in which aldehyde toxicity is implicated in the pathogenesis by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.

The present disclosure relates generally to various forms and compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase and uses of the same in the treatment of c-kit kinase associated diseases.

Crystalline forms of a selective c-kit kinase inhibitor

The present invention provides compounds of formula I useful as inhibitors of Tyrosine Kinase 2 (Tyk2) solid forms and compositions thereof, methods of producing the same, and methods of using the same in the treatment of Tyk2-mediated diseases.

TYK2 inhibitors, uses, and methods for production thereof

The present disclosure relates to pharmaceutical sciences and chemical sciences. In particular, the present disclosure provides crystalline platinum-based compound IO-125, compositions and formulations comprising the same, along with method of preparing said crystalline compound, and uses thereof. 

Crystalline platinum-based compounds

The present invention provides compounds useful as inhibitors of Tyrosine Kinase 2 (Tyk2), solid forms and compositions thereof, methods of producing the same, and methods of using the same in the treatment of Tyk2-mediated diseases.

Growing community of inventors

Edinburgh, United Kingdom

Jonathan James Loughrey